Galapagos and The ALS Assoc in 2.4M euros accord
Mechelen, Belgium-based Galapagos NV ) and the ALS Association, a non-profit health organization dedicated to finding a cure for amyotrophic lateral sclerosis, have entered a new two-year target discovery alliance. Galapagos' service division BioFocus DPI will apply its adenoviral platform to identify drug targets for the development of new ALS therapies.
Under the terms of the agreement, Galapagos may receive up to 2.4 million euros ($3.0 million) from the Association. In addition, Galapagos has the option to further develop certain targets identified in the program.
Key to the identification of ALS targets is the cell model representing the disease process in ALS. In this project, BioFocus DPI will screen its adenoviral SilenceSelect collection in human motor neurons.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze